267 related articles for article (PubMed ID: 24086139)
41. K63-Linked Ubiquitin Is Required for Restriction of HIV-1 Reverse Transcription and Capsid Destabilization by Rhesus TRIM5α.
Imam S; Kömürlü S; Mattick J; Selyutina A; Talley S; Eddins A; Diaz-Griffero F; Campbell EM
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068426
[TBL] [Abstract][Full Text] [Related]
42. Binding of the rhesus TRIM5α PRYSPRY domain to capsid is necessary but not sufficient for HIV-1 restriction.
Yang Y; Brandariz-Nuñez A; Fricke T; Ivanov DN; Sarnak Z; Diaz-Griffero F
Virology; 2014 Jan; 448():217-28. PubMed ID: 24314652
[TBL] [Abstract][Full Text] [Related]
43. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.
Stremlau M; Perron M; Welikala S; Sodroski J
J Virol; 2005 Mar; 79(5):3139-45. PubMed ID: 15709033
[TBL] [Abstract][Full Text] [Related]
44. A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection.
Humes D; Emery S; Laws E; Overbaugh J
J Virol; 2012 Dec; 86(23):12472-83. PubMed ID: 22973036
[TBL] [Abstract][Full Text] [Related]
45. Proteasomal degradation of TRIM5alpha during retrovirus restriction.
Rold CJ; Aiken C
PLoS Pathog; 2008 May; 4(5):e1000074. PubMed ID: 18497858
[TBL] [Abstract][Full Text] [Related]
46. Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.
Takeuchi H; Buckler-White A; Goila-Gaur R; Miyagi E; Khan MA; Opi S; Kao S; Sokolskaja E; Pertel T; Luban J; Strebel K
J Virol; 2007 Aug; 81(15):8080-90. PubMed ID: 17522232
[TBL] [Abstract][Full Text] [Related]
47. Distinct combinations of amino acid substitutions in N-terminal domain of Gag-capsid afford HIV-1 resistance to rhesus TRIM5α.
Nomaguchi M; Nakayama EE; Yokoyama M; Doi N; Igarashi T; Shioda T; Sato H; Adachi A
Microbes Infect; 2014 Nov; 16(11):936-44. PubMed ID: 25195168
[TBL] [Abstract][Full Text] [Related]
48. Cytoplasmic body component TRIM5{alpha} requires lipid-enriched microdomains for efficient HIV-1 restriction.
Ohmine S; Sakuma R; Sakuma T; Thatava T; Solis GP; Ikeda Y
J Biol Chem; 2010 Nov; 285(45):34508-17. PubMed ID: 20810659
[TBL] [Abstract][Full Text] [Related]
49. Contribution of glutamine residues in the helix 4-5 loop to capsid-capsid interactions in simian immunodeficiency virus of macaques.
Tipper C; Sodroski JG
J Virol; 2014 Sep; 88(18):10289-302. PubMed ID: 24991000
[TBL] [Abstract][Full Text] [Related]
50. Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains.
Li X; Li Y; Stremlau M; Yuan W; Song B; Perron M; Sodroski J
J Virol; 2006 Jul; 80(13):6198-206. PubMed ID: 16775307
[TBL] [Abstract][Full Text] [Related]
51. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors.
Hultquist JF; Binka M; LaRue RS; Simon V; Harris RS
J Virol; 2012 Mar; 86(5):2874-7. PubMed ID: 22205746
[TBL] [Abstract][Full Text] [Related]
52. p62/sequestosome-1 associates with and sustains the expression of retroviral restriction factor TRIM5alpha.
O'Connor C; Pertel T; Gray S; Robia SL; Bakowska JC; Luban J; Campbell EM
J Virol; 2010 Jun; 84(12):5997-6006. PubMed ID: 20357094
[TBL] [Abstract][Full Text] [Related]
53. Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals.
Ylinen LM; Keckesova Z; Webb BL; Gifford RJ; Smith TP; Towers GJ
J Virol; 2006 Aug; 80(15):7332-8. PubMed ID: 16840314
[TBL] [Abstract][Full Text] [Related]
54. TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner.
Ohainle M; Kim K; Komurlu Keceli S; Felton A; Campbell E; Luban J; Emerman M
PLoS Pathog; 2020 Apr; 16(4):e1008507. PubMed ID: 32282853
[TBL] [Abstract][Full Text] [Related]
55. Dynamic conformational changes in the rhesus TRIM5α dimer dictate the potency of HIV-1 restriction.
Lamichhane R; Mukherjee S; Smolin N; Pauszek RF; Bradley M; Sastri J; Robia SL; Millar D; Campbell EM
Virology; 2017 Jan; 500():161-168. PubMed ID: 27821283
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
[TBL] [Abstract][Full Text] [Related]
57. Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type.
Matsuoka S; Dam E; Lecossier D; Clavel F; Hance AJ
Retrovirology; 2009 Mar; 6():21. PubMed ID: 19254360
[TBL] [Abstract][Full Text] [Related]
58. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.
Speelmon EC; Livingston-Rosanoff D; Li SS; Vu Q; Bui J; Geraghty DE; Zhao LP; McElrath MJ
J Virol; 2006 Mar; 80(5):2463-71. PubMed ID: 16474153
[TBL] [Abstract][Full Text] [Related]
59. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells.
Sokolskaja E; Berthoux L; Luban J
J Virol; 2006 Mar; 80(6):2855-62. PubMed ID: 16501094
[TBL] [Abstract][Full Text] [Related]
60. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.
Stremlau M; Owens CM; Perron MJ; Kiessling M; Autissier P; Sodroski J
Nature; 2004 Feb; 427(6977):848-53. PubMed ID: 14985764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
